Teriflunomide induces a tolerogenic bias in blood immune cells of MS patients

OBJECTIVES: Teriflunomide, a disease‐modifying treatment approved for multiple sclerosis (MS), inhibits reversibly dihydroorotate dehydrogenase, an enzyme involved in de novo pyrimidine biosynthesis and down‐regulates proliferation of activated lymphocytes. We aimed to study the impact of this drug...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Ann Clin Transl Neurol
Egile Nagusiak: Medina, Silvia, Sainz de la Maza, Susana, Villarrubia, Noelia, Álvarez‐Lafuente, Roberto, Costa‐Frossard, Lucienne, Arroyo, Rafael, Monreal, Enric, Tejeda‐Velarde, Amalia, Rodríguez‐Martín, Eulalia, Roldán, Ernesto, Álvarez‐Cermeño, José C., Villar, Luisa M.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley and Sons Inc. 2019
Gaiak:
Research Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6389853/
https://ncbi.nlm.nih.gov/pubmed/30847367
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/acn3.711
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak